iShares Genomics Immunology and Healthcare ETF (IDNA)
NYSEARCA: IDNA · Real-Time Price · USD
42.05
+0.77 (1.87%)
Oct 15, 2026, 4:00 PM EDT - Market closed
| Assets | $315.08M |
| Expense Ratio | 0.47% |
| PE Ratio | 20.95 |
| Forward PE | 16.96 |
| Shares Out | 7.60M |
| Dividend | $0.28 (0.67%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Payout Frequency | Semi-Annual |
| Payout Ratio | 14.15% |
| Volume | 107,612 |
| Open | 41.95 |
| Previous Close | 41.28 |
| Day's Range | 41.67 - 42.12 |
| 52-Week Low | 24.24 |
| 52-Week High | 43.44 |
| Beta | 0.93 |
| Holdings | 62 |
| Inception Date | Jun 11, 2019 |
About IDNA
Fund Home PageThe iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is issued by BlackRock.
Asset Class Equity
Category Health
Stock Exchange NYSE Arca
Ticker Symbol IDNA
ETF Provider BlackRock
Index Tracked NYSE FactSet Global Genomics and Immuno Biopharma Index
Top 10 Holdings
49.68% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 13.58% |
| Twist Bioscience Corporation | TWST | 6.09% |
| Iovance Biotherapeutics, Inc. | IOVA | 4.93% |
| Genmab A/S | GMAB | 4.26% |
| Revolution Medicines, Inc. | RVMD | 3.69% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.49% |
| Merck & Co., Inc. | MRK | 3.47% |
| Takeda Pharmaceutical Company Limited | 4502 | 3.43% |
| Bayer Aktiengesellschaft | BAYN | 3.41% |
| ImmunityBio, Inc. | IBRX | 3.33% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 15, 2026 | $0.12542 | Jun 18, 2026 |
| Dec 16, 2025 | $0.15546 | Dec 19, 2025 |
| Jun 16, 2025 | $0.15291 | Jun 20, 2025 |
| Dec 17, 2024 | $0.11105 | Dec 20, 2024 |
| Jun 11, 2024 | $0.11144 | Jun 17, 2024 |
| Dec 20, 2023 | $0.16925 | Dec 27, 2023 |
Performance
IDNA had a total return of 75.24% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.42%.
News
Best Biotech ETFs for Q2 2021
The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI.
5 years ago - Investopedia